bio-germ产品代理
bio-germ产品代理
伯杰医疗是一家集研发、生产、销售于一体的医疗器械制造公司，其总部坐落在上海奉贤区凤创谷，拥有试剂研发生产中心、标准生产厂房、仪器研发生产中心和技术服务中心，共占地13000㎡，公司生产车间已通过ISO 13485质量管理体系的认证。公司还拥有两家第三方医学检验实验室，已通过生物安全二级实验室备案，具备新冠和其他病原体核酸检测资质。此外伯杰医疗还在全国设立多家办事处及子公司，以便于更好地服务全国近3000家临床和科研单位客户。
Diagnostic Reagents
Instruments
Sequencing Services
Clinical Laboratory
Shanghai BioGerm Medical Technology Co., Ltd (hereinafter referred to as “BioGerm”) was established in March 2017. It is a high-tech company dedicated to the development and application of molecular diagnostic reagents for infectious pathogens, especially multiple fluorescent PCR diagnostic reagents. With the main focus on infectious pathogens, the company provides a complete set of solutions for emergency response of epidemics to reduce the waiting time for outpatients by one hour, so that patients with serious medical problems can receive accurate treatment.
Located in Shanghai Phoenix Creativity Valley, the main body of BioGerm has a 6,000 square meters of clean plant which is used for the development and production of reagent and instrument, used for technical service and standard GMP production.
The company’s wholly-owned medical laboratory is located in Pudong International Medical Park, covering an area of 1,000 square meters, which is already qualified for molecular genetics and microbial testing. It is a registered level 2 biosafety laboratory with the certification in both ISO 9001 and 13485.
BioGerm can quickly respond to this novel coronavirus epidemic in the early stage is also due to the company’s dedication and long-term accumulation in the field of respiratory virus nucleic acid diagnostic reagents and sequencing services. Before the outbreak, more than 400 nucleic acid detection reagents and three different nucleic acid extraction reagents developed by BioGerm have been widely used in most Chinese Center for Disease Control and Prevention. In the early stages of the epidemic, BioGerm took the advantage of emergency R & D and production in the field of respiratory viruses and took the lead in completing the development of the kit, which ensures that the suspected infection is diagnosed in the early stages of the epidemic. Later, the Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit（PCR-Fluorescence Probing）was approved by the National Medical Products Administration and was expropriated by the Shanghai Government for epidemic prevention and control.
At present, BioGerm has more than 400 kinds of pathogenic nucleic acid detection kits, including 2019-nCoV, with self-developed nucleic acid extraction reagents, the first generation of the three automatic nucleic acid extraction instrument and the second generation of nucleic acid extraction workstation has been widely used.
